These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 29304362)

  • 1. Leptomeningeal metastases in non-small-cell lung cancer.
    Cheng H; Perez-Soler R
    Lancet Oncol; 2018 Jan; 19(1):e43-e55. PubMed ID: 29304362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
    Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells.
    Jiang BY; Li YS; Guo WB; Zhang XC; Chen ZH; Su J; Zhong WZ; Yang XN; Yang JJ; Shao Y; Huang B; Liu YH; Zhou Q; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Wu SY; Gao CY; Zhang X; Wu YL
    Clin Cancer Res; 2017 Sep; 23(18):5480-5488. PubMed ID: 28606923
    [No Abstract]   [Full Text] [Related]  

  • 4. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
    Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
    Sakata Y; Kawamura K; Shingu N; Ichikado K
    Lung Cancer; 2016 Sep; 99():120-2. PubMed ID: 27565925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.
    Alexander M; Lin E; Cheng H
    Curr Treat Options Oncol; 2020 Jul; 21(9):72. PubMed ID: 32725549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
    Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
    J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
    [No Abstract]   [Full Text] [Related]  

  • 8. [Leptomeningeal metastasis of EGFR (+) lung adenocarcinoma: a case report].
    Güçsav MO; Ayrancı A; Polat G; Karadeniz G; Demirci Üçsular F; Öztekin Ö; Bozkurt MT; Akyol M; Yalnız E
    Tuberk Toraks; 2018 Dec; 66(4):340-344. PubMed ID: 30683030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
    Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
    Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
    Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
    Zhang I; Zaorsky NG; Palmer JD; Mehra R; Lu B
    Lancet Oncol; 2015 Oct; 16(13):e510-21. PubMed ID: 26433824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Yin K; Li YS; Zheng MM; Jiang BY; Li WF; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Yang XN; Chen HJ; Yan HH; Li LL; Wu YL; Zhang XC
    Lung Cancer; 2019 May; 131():134-138. PubMed ID: 31027690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing central nervous system metastases in non-small cell lung cancer.
    Krawczyk P; Duchnowska R; Nicoś M; Kowalski D; Wojas-Krawczyk K
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1077-1083. PubMed ID: 30198357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.
    Smalley KS; Fedorenko IV; Kenchappa RS; Sahebjam S; Forsyth PA
    Int J Cancer; 2016 Sep; 139(6):1195-201. PubMed ID: 27084046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
    Umemura S; Tsubouchi K; Yoshioka H; Hotta K; Takigawa N; Fujiwara K; Horita N; Segawa Y; Hamada N; Takata I; Yamane H; Kamei H; Kiura K; Tanimoto M
    Lung Cancer; 2012 Jul; 77(1):134-9. PubMed ID: 22487432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer].
    Lu Z; Cai J; Zeng Z; Liu A
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):710-718. PubMed ID: 32758347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress of lung cancer with leptomeningeal metastasis].
    Ma C; Jiang R; Li J; Wang B; Sun L; Lv Y
    Zhongguo Fei Ai Za Zhi; 2014 Sep; 17(9):695-700. PubMed ID: 25248713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.
    Ojerholm E; Lee JY; Thawani JP; Miller D; O'Rourke DM; Dorsey JF; Geiger GA; Nagda S; Kolker JD; Lustig RA; Alonso-Basanta M
    J Neurosurg; 2014 Dec; 121 Suppl():75-83. PubMed ID: 25434940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy.
    Chamberlain MC; Kormanik P
    Arch Neurol; 1998 Apr; 55(4):506-12. PubMed ID: 9561978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.